Cost-Utility Analysis of 177Lu–PSMA-617 Radioligand Therapy in Second-Line and Third-Line Treatment for Metastatic Castration-Resistant Prostate Cancer(mCRPC) in Germany
Hamburg Center for Health Economics – Prof. Dr. Tom Stargardt & Carolin Brinkmann
This study aims to assess the cost-effectiveness of 177Lu-PSMA-617 radioligand therapy (PRLT) for patients with metastatic castration-resistant prostate cancer (mCRPC). Two specific comparisons will be made: Model I compares PRLT plus standard of care (SoC) with SoC alone as a third-line treatment. Model II compares PRLT plus SoC with second-line cabazitaxel chemotherapy, assuming second-line values are equivalent to those of third-line treatments.

menuchevron-downarrow-upcross-circle